Alembic Pharmaceuticals Ltd (APLLTD) — shareholding pattern, promoter holding, financials and share price
About Alembic Pharmaceuticals Ltd (APLLTD)
Alembic Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as APLLTD and on the BSE under scrip code 533573. Its ISIN is INE901L01018.
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals).
Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend.
Listed peers in Pharmaceuticals: OneSource Specialty Pharma Ltd, Natco Pharma Ltd, Cohance Lifesciences Ltd, Jubilant Pharmova Ltd, Alivus Life Sciences Ltd, Concord Biotech Ltd.
Valuation & Returns
10 Jul 2026At ₹837.45 a share on 10 Jul 2026, Alembic Pharmaceuticals Ltd (APLLTD) was valued at a price-to-earnings ratio of 24.54x against an industry P/E of 36.41x and a price-to-book of 3.17x on a book value of ₹264.09 per share as of Mar 2025. Solomo computes return on equity of 12.92% and return on capital employed of 12.21% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 24.54x
- Industry P/E
- 36.41x
- P/B
- 3.17x
- EPS (TTM)
- ₹34.13
- Book value / share
- ₹264.09
- ROE
- 12.92%
- ROCE
- 12.21%
- ROA
- 8.63%
- Debt / equity
- 0.24x
- Dividend yield
- 1.31%
- EBITDA margin
- 15.06%
- 52-week range
- ₹635.3 – ₹1,064.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Alembic Pharmaceuticals Ltd (APLLTD) reported revenue of ₹7,345 crore, net profit of ₹671 crore and earnings per share of ₹34.33. That compares with revenue of ₹6,672 crore and net profit of ₹582 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,848 crore and net profit ₹202 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 |
| Net profit (₹ cr) | 521 | 342 | 616 | 582 | 671 |
| EPS (₹) | 26.5 | 17.4 | 31.33 | 29.68 | 34.33 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.04% | 7.86% | 6.21% | 7.12% |
| Profit growth | -3.58% | -12.29% | -2.54% | -5.49% |
| Stock price CAGR | 4% | -3% | 8% | -18% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 69.87% of Alembic Pharmaceuticals Ltd (APLLTD) (up 0.13 pp QoQ), foreign institutional investors (FII) hold 4.18% and domestic institutional investors (DII) hold 15.94%. Market capitalisation was ₹16,461 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2011.
Largest disclosed public shareholders in Jun 2026: Life Insurance Corporation Of India 4.32%, Dsp Small Cap Fund 3.86%, Kotak Small Cap Fund 1.74%, Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 1.38%, Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund 1.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 69.87% | - | 4.18% | 15.94% | 30.13% |
| Mar 2026 | 69.74% | - | 4.25% | 16.18% | 30.26% |
| Dec 2025 | 69.74% | - | 4.24% | 16.17% | 30.26% |
| Sep 2025 | 69.74% | - | 4.05% | 16.3% | 30.26% |
| Jun 2025 | 69.67% | - | 3.96% | 16.46% | 30.33% |
| Mar 2025 | 69.67% | - | 3.94% | 16.43% | 30.33% |
| Dec 2024 | 69.61% | - | 4.17% | 16.06% | 30.39% |
| Sep 2024 | 69.61% | - | 3.94% | 16.05% | 30.39% |